Hormonal
In Type 2 Diabetes patients, increased plasma Interleukin-6 (IL-6) levels are significantly correlated with the abundance of Gram-negative gut bacteria, specifically Prevotella copri and Bacteroides vulgatus, suggesting these microbes drive systemic inflammation and insulin resistance.
This research highlights that in Type 2 Diabetes, high levels of specific gut bacteria (Prevotella and Bacteroides) are linked to higher inflammation (IL-6) and insulin resistance. While this paper does not prescribe a treatment, it suggests that managing gut health through diet may be a relevant factor in addressing the inflammatory component of diabetes, alongside standard medical care.
The proinflammatory interleukin-6 (IL-6) was significantly increased (P < 0.05) in patients’ plasma... We find correlations between the proinflammatory interferon-gamma with Gram-negatives Bacteroides and Prevotella species, and a positive correlation between the LPS levels and P. copri reads... we suggested that the prevalence of Gram-negative species in the gut and the increased plasma IL-6 in patients could be linked to low-grade inflammation and insulin resistance.
Why this rating
Small sample size (n=20 patients, n=22 controls) and observational design limit causal inference, though statistical significance is reported.
Source
Detection of Increased Plasma Interleukin-6 Levels and Prevalence of Prevotella copri and Bacteroides vulgatus in the Feces of Type 2 Diabetes Patients
Aline Zazeri Leite et al. · Frontiers in Immunology · 2017
DOI 10.3389/fimmu.2017.01107
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →